krn-7000 has been researched along with Brain-Neoplasms* in 2 studies
2 other study(ies) available for krn-7000 and Brain-Neoplasms
| Article | Year |
|---|---|
Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma.
Topics: Animals; Antigens, Neoplasm; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Disease Models, Animal; Galactosylceramides; Humans; Immunization; Lymphocyte Activation; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Natural Killer T-Cells; Peptides; T-Lymphocytes | 2020 |
Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma.
Dendritic cell (DC) vaccine-based immunotherapy for glioblastoma multiforme (GBM) has shown apparent benefit in animal experiments and early-phase clinical trials, but the survival benefit is variable. In this work, we analyzed the mechanism of the potent antitumor immune response induced in vivo by tumor-associated antigen (TAA)-specific DCs with an invariant natural killer T (iNKT) cell adjuvant in orthotopic glioblastoma-bearing rats vaccinated with tumor-derived exosomes and α-galactosylceramide (α-GalCer) -pulsed DCs. Compared with traditional tumor lysate, exosomes were utilized as a more potent antigen to load DCs. iNKT cells, as an effective cellular adjuvant activated by α-GalCer, strengthened TAA presentation through their interaction with DCs. Co-delivery of tumor-derived exosomes with α-GalCer on a DC-based vaccine showed powerful effects in glioblastoma immunotherapy. This vaccine induced strong activation and proliferation of tumor-specific cytotoxic T lymphocytes, synergistically breaking the immune tolerance and improving the immunosuppressive environment. Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dendritic Cells; Exosomes; Flow Cytometry; Galactosylceramides; Glioblastoma; Immunotherapy, Adoptive; Male; Natural Killer T-Cells; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2017 |